Publications

Skip to content

New and Noteworthy

Gastric/Esophageal cancer

Topics

Publications

Breast cancer

Small cell lung cancer

Renal cell carcinoma

Real-world evidence

Unmet need

Melanoma

Drug discovery

Treatment patterns

Non-small cell lung cancer

Hepatocellular carcinoma

Methodology

Head and neck cancer

Colorectal cancer

Pancreatic cancer

Content type

Publication summary

Showing 7 of 0 results

Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval
JAMA Oncology
Analysis of a real-world progression variable and related endpoints for patients with five different cancer types
Advances in Therapy
ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA)
ASCO Annual Meeting
Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: insights from routine practice
Cancer
Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer patients (pts)
ASCO GI Symposium
Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors
ASCO Annual Meeting
Chemotherapy use near end of life (EOL): measuring real world benchmarks
ASCO Quality Care Symposium

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Clinical Research
Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Data Confidentiality Commitments
Cookie Settings
© FLATIRON HEALTH® 2024